Introduction: The CMC requirements 505(b)(2) NDA applicants must satisfy are the same quality standards that apply to any new drug […]
CMC Requirements for 505(b)(2) NDA Pathway: What Makes It Different from a Full NDA Read More »
Introduction A well-prepared Common Technical Document (CTD) Module 3 serves as a comprehensive, reviewer-ready Chemistry, Manufacturing, and Controls (CMC) quality
Regulatory CMC Writing Services: What a Well-Prepared CTD Module 3 Looks Like Read More »
Introduction Scale-Up and Tech Transfer in CMC represents a critical operational pathway through which bench-scale drug formulation and synthesis are
Introduction FDA expectations for Extractables and Leachables in CMC require pharmaceutical sponsors to demonstrate chemical compatibility through risk-based material characterization,
Introduction: Microsampling techniques in bioanalysis have moved well beyond the dried blood spot card, because modern drug development needs smaller
Introduction Contract development and manufacturing organizations (CDMOs) that initially specialized in synthetic peptides have expanded their capabilities into nucleic acid
Introduction Evaluating COC and COP containers as glass alternatives highlights an advanced primary packaging strategy for sensitive biologics, parenteral formulations,
COC and COP Containers as Glass Alternatives: What Their Extractables Profiles Reveal Read More »
Introduction Uncontrolled migration of non-bonded plasticizers and the sorption of therapeutic drugs remain two major material-compatibility challenges associated with polyvinyl
Introduction: Sterilization changes an extractables and leachables profile because heat, radiation, or reactive gas alters the polymers, additives, and residues
Introduction Establishing robust Oligonucleotide CMC Specifications requires addressing unique regulatory challenges because therapeutic oligonucleotides possess physical, chemical, and structural characteristics
